<?xml version="1.0" encoding="UTF-8"?>
<p>Finally, on 2 June 2019—almost four months after the process to revise the protocol to include pregnant women was initiated by SAGE—the DRC Ministry of Health announced that the National Ethics Committee at the School of Public Health at the University of Kinshasa had granted their approval to an amended vaccination protocol that would allow the administration of the Merck rVSV-ZEBOV vaccine to pregnant women beyond their first trimester of pregnancy and to lactating women if they were identified as case contacts. The committee continued to maintain that only children over the age of 6 should be vaccinated [
 <xref rid="B12-vaccines-08-00038" ref-type="bibr">12</xref>,
 <xref rid="B15-vaccines-08-00038" ref-type="bibr">15</xref>]. It had taken over 4 years for pregnant and breastfeeding women to receive EVD vaccination since the initial clinical trials [
 <xref rid="B11-vaccines-08-00038" ref-type="bibr">11</xref>]. The first pregnant women finally received the rVSV-ZEBOV vaccine on 13 June—almost 10 months after the outbreak began. According to Dr. Carleigh Krubiner, a Policy Fellow at the Center for Global Development [
 <xref rid="B15-vaccines-08-00038" ref-type="bibr">15</xref>]:
</p>
